Oncompass Medicine

Approved by Diagnose.me Medical Advisory Board on 04 Aug 2017

Oncompass Medicine


Institution ONCOMPASS™ helps cancer patients and treating doctors to find the most appropriate personalized cancer treatments. Our method is based on molecular diagnostics, and applies a unique software tool powered by artificial intelligence processing scientific discoveries and experience across the globe.

Consultation Report
Delivery time
5 workdays
Video Consultation
About us

ONCOMPASS™ Medicine is an international molecular diagnostic-based therapeutic information and decision support service for precision oncology, which helps oncologists to define the most appropriate cancer treatment strategy for their patients, and supports patients to find access to the best personalized cancer therapies based on a unique clinical interpretation of molecular diagnostic results.

Oncompass Molecular Tumour Board develops information technology methods and systems for selecting the right molecular diagnostics and provide clinical interpretation of the molecular genetic alterations in cancer.

Oncompass collaborates with oncologists to provide pertinent molecular and clinical information in order to evaluate treatment options, helps patients to get access to novel therapies and clinical trials.

Through its affiliate, Oncompass Medicine Hungary, founded in 2003, or through its German an US lab partners, Oncompass can provide also state of the art, NGS based multi-gene and FISH testing and IHC for cancer patients in Europe.

Oncompass operates through a Swiss, and a Hungarian operating entity, receiving samples across Europe. Recently the Company launched additional presence through affiliates or distributors in Romania, Czech Republic, Bulgaria, Poland, Austria, Germany, Russia and Turkey and plans to enter the US in 2018 with its new, cloud-based, Clinical Decision Support System, the Precision Medicine CalculatorTM. The Calculator uses patented algorithms and artificial intelligence to process thousands of novel scientific- and clinical evidences of thousands of patients to find the best available treatment options.

Oncompass Medicine, founded 14 years ago by 2 physicians and researcher, has several times in its history pioneered the use of molecular diagnostics for supporting clinical cancer treatment strategies. For example, in 2003, for the first time ever, a patient was prospectively given a targeted therapy to correspond to its EGFR driver gene mutation. The treatment resulted in a multi-year progression free survival. One of the founders, Dr Istvan Petak, Phd., is a regular speaker at international conferences about personalized oncology and molecular diagnostics (e.g.at the annual conference of the European Society for Medical Oncology, or at the Personalized Medicine World Conference in San Francisco).

Oncompass is owned by private individuals (including reputable European scientists and doctors, and international healthcare investors) and PortfoLion, (a Venture Capital Fund under the JEREMIE program of the European Commission).

Assoc. Prof. Istvan Petak, MD, PhD

SPECIALTIES: physician, molecular pharmacologist, expert in molecular oncology, trained in the US (Fulbright Scholar)  •  EXPERIENCE: 20 years
MD, Phd, founder and Scientific Director of Oncompass, molecular pharmacologist trained in the US (Fulbright Scholar) and in Hungary. He is a lecturer at the University of Illinois at Chicago, and at the Semmelweis University, Budapest. He is one of the pioneers of molecular diagnostics of targeted therapies worldwide, with several important publications (eg. in Nature Reviews Drug Disc., Journal of Mol. Diagn.). He is the inventor of the Precision Medicine Calculator, the first of its kind decision support program to help oncologists and patients to find the right personalized treatment strategy. He has been invited speaker in several international oncological conferences (eg. most recently at ESMO (European Society of Medical Oncology in 2017). He is a member of ESMO, ASCO (American Socitey of Clinical Oncology), Swiss Group for Clinical Cancer Research. He has also been advisory board member in global “molecular” boards of large pharma companies.
Licensures and memberships
  • n/a, Switzerland
Report languages

English, plus 22 languages with medical translation